

FIG. 1




FIG. 2




FIG. 3




FIG. 4




Fig. 4A

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit Discuss

Address Back to Journalsoft Manuscript Management System

My JournalSoft

View Manuscripts

Personal Data

Preferences

MetaData

Help

Logout

Journalsoft

You are logged in with EDITOR privileges

MANUSCRIPTS TO REVIEW

You have completed 5 reviews. Thank you.
To view the reviews please click on the thumb icons.

YOUR COMPLETED REVIEWS


👍 = Suggest acceptance.
👎 = Suggest major or minor revisions.
👎 = Suggest rejection.

<p>99-121 George, Timothy <i>et al.</i> Influence of PZ Immortalization of Human Neuroblasts on P73-Dependent Radiation Responses.</p>	<p>👎 Your review received 4 day(s) late on 22-Jan-1999.</p> <p>👍 Other review received on 21-Jan-1999.</p> <p>Declined publication on 21-Jan-1999</p>
<p>99-127 Chinook, Arvin <i>et al.</i> The Apoptosome: Heart and Soul of the Cell Death Machine.</p>	<p>Your review received on 19-Jan-1999</p> <p>Other review received on 18-Jan-1999</p> <p>Accepted pending minor revision on 19-Jan-1999 Revisions Due by 19-Feb-1999</p>
<p>99-148 Cummings, C.D. <i>et al.</i> The effect of cysteine in combination with vitamin K on the activity of ornithine carboxylase of malignant cells in vitro.</p>	<p>Your review received on 24-Feb-1999</p> <p>Other review received on 24-Feb-1999</p> <p>Declined publication on 24-Feb-1999</p>
<p>99-178 Pantoris, Paul <i>et al.</i> The anticancer drug 9-tetosecan converts human malignant melanoma cells to a pre-malignant state: Correlation with alterations in the expression of the cyclin-dependent kinase inhibitors.</p>	<p>Your review received on 01-Apr-1999</p> <p>Other review received on 01-Apr-1999</p> <p>Will reconsider following major revision (02-Apr-1999) Revisions due by 03-May-1999</p>
<p>99-229 Thomas, David <i>et al.</i> Increased expression of the wild type p37 gene in malignant mesotheliomas.</p>	<p>Your review received on 10-Jun-1999</p> <p>Other review received on 08-Jun-1999</p> <p>Declined publication on 11-Jun-1999</p>

1 Hierarchical Menu Trees Created

Internet

Fig. 4B



Martin Block

Paper Sent:
11-Dec-1998Review Due:
25-Dec-1998Review Received:
22-Dec-1998

RECOMMENDATION

Accept ☒

THIS REVIEW IS MARKED AS A DRAFT.
 IT HAS NOT YET BEEN MADE AVAILABLE TO THE EDITORS AND
 AUTHORS.

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Significance	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Originality	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clarity	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure.

Unfortunately the difference between the radiosensitization of the two

E7-expressing clones and the parental cells is not as convincing as

one would have liked. There also seem to be discrepancies between

some of the reported data in the text and the tables (see below).

<U>Specific Comments</U>

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater

THIS REVIEW IS CURRENTLY MARKED AS A DRAFT




FIG. 5




FIG. 6

RATINGS	Top 5%	Top 10%	Top 25%	Top 50%	Bottom 50%	No Comment
Scientific Quality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Significance	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Originality	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Clarity	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

COMMENTS TO THE AUTHORS

This study is a very nice experiment to validate the authors' hypothesis that radiosensitization FdUrd exposure depends on progression of cells through the S phase during drug exposure. Unfortunately the difference between the radiosensitization of the two E7-expressing clones and the parental cells is not as convincing as one would have liked. There also seem to be discrepancies between some of the reported data in the text and the tables (see below).

Specific Comments

1. Table I: The TS activity in the E7.9 clone during FdUrd exposure is much larger than that of the controls and is certainly not greater than 95% inhibited as indicated in the text (p. 8, par. 1).
2. Figure 1: Why are the data for only one experiment shown? It would seem to make more sense to show the data for all experiments with mean and standard errors for each point for the pooled data.

We are sorry that the reviewer seemed confused by this figure. In fact, it was a plot of mean values. We have added error bars and refined the caption to make this more clear.

3. P. 5, par. 3: The use of mean inactivation dose is perhaps the best way to analyze data fitted with the linear-quadratic model, but it is really an arcane method that will not be understood by 95% of the readers. If the authors have to use this method, they should indicate that the method heavily weights the initial part of the survival curve (for example, all data above 10% surviving fraction) and therefore, heavily weights the alpha component




FIG. 7




FIG. 8




Fig. 9

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links

Journalsoft

To register for JournalSoft, please fill out the form.

Fill out the form below completely to register.

1. Your Login Information

Username
Please enter the username you would like to use to login to JournalSoft.

Password
Please enter a password that you can easily remember. Passwords are case-sensitive and should contain between 3 and 10 characters. The most secure passwords contain letters and numbers.

Please enter your favorite password:

Confirm password:

Please enter your main EMAIL address:

You may enter a clue to your password to help you remember it in the future:

Done Internet


Fig. 10

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links



To register for JournalSoft, please fill out the form.

1. Fill out the form below completely to register.

2. Enter your contact information below.

Name:	<input type="text"/>		
Address:	<input type="text"/>		
City, State and Zip Code:	<input type="text"/>	<input type="text"/>	<input type="text"/>
Country:	<input type="text"/>		
Phone:	<input type="text"/>	(Not Required)	
Fax:	<input type="text"/>	(Not Required)	
Text Pager Email or Web Paging Address:	<input type="text"/>	(Not Required)	
If you have a Web Site, you can include your URL in the AD	Enter exactly as shown here: www.yourdomain.com DO NOT BEGIN YOUR ADDRESS WITH "http://" <input type="text"/>		

Done Internet

Fig. 11




Fig. 12





Fig. 13

Journalsoft Manuscript Management System - Microsoft Internet Explorer

File Edit View Favorites Tools Help

Back Forward Stop Refresh Home Search Favorites History Mail Print Edit

Address Links



To register for JournalSoft, please fill out the form.

JOURNALSOFT.COM

Fill out the form below completely to register.

5. JournalSoft Preferences.

Please enter your preferences so we can customize your JournalSoft experience

Please remember that you can change these options at any time in the future.

Would you like to review papers for Neoplasia?	<input type="radio"/> YES <input type="radio"/> NO
If so, please enter any dates when you will not be available to review manuscripts (MMDDYY-MMDDYY) Enter each separate period on a new line.	<input style="width: 100%;" type="text"/>
How would you like us to request reviews from you?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.
How would you like us to notify you when a manuscript which you have submitted passes through a peer-review milestone such as a review being recieved or an editorial decision being made?	<input type="radio"/> On your JournalSoft webpage only. <input type="radio"/> By E-Mail. <input type="radio"/> By Phone. <input type="radio"/> By Fax. <input type="radio"/> By Text Pager.

Done Internet

Fig. 14




Fig. 15




Fig. 16

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKewed/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.